Thanh Ha Vu

3PUBLICATIONS
8CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Oct 22, 2025
Real-World Evidence for First-Line afatinib in Advanced Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations Other than G719X/L861Q/S768I.

Thanh Ha Vu, Hoa Thai Thi Nguyen, To Van Ta

|Oct 21, 2025
Optimizing afatinib dosage: enhancing treatment outcomes and minimizing toxicities in advanced EGFR-mutated non-small cell lung cancer patients in Vietnam.

Cam Phuong Pham, Hung Kien Do, Anh Tu Do

|May 25, 2025
Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam.

Van Luan Pham, Cam Phuong Pham, Thi Thai Hoa Nguyen

Pageof 1

Frequent Collaborators

3 joint publications

Minh Cong Truong

2 joint publications

Van Luan Pham

2 joint publications

Hung Kien Do

1 joint publications

Cam Phuong Pham